CBI is proud to expand on its drug safety series with the inaugural Safety Assessment of Serious Adverse Events in CNS.  During various stages of the pre-clinical and clinical development process, experimental drugs are frequently found to produce adverse CNS side effects.  While such findings do not often result in immediate discontinuation of a drug’s development it is important to have procedures in place to predict, monitor and report serious adverse events such as abuse and addiction potential, seizure liability and suicidality.

Conference Highlights Include:

• Suicidality Monitoring in Clinical Trials – Overview of the Columbia Suicide Severity Rating Scale (C-SSRS)

• Novel Approaches in Pre-clinical Seizure Detection and Prediction Using EEG

• FDA Draft Guidance for Industry on Abuse Potential Assessment of New Drugs – Relevant Adverse Events Analysis in Clinical Trials 

• Investigating CNS Serious Adverse Events Associated With ADHD Treatments

• Safety Evaluation of SSRIs and Other Antidepressants

Sponsors/Exhibitors:

For more information or to register, please contact the Center for Business Intelligence toll free by phone at 1-800-817-8601 or via e-mail at cbireg@cbinet.com.